ММВБ 2 906 0,2%  Nasdaq 8 571 0,1%  Биткойн 7 376 -0,4%  USD/RUB 63,7245 0,0% 
РТС 1 436 0,4%  S&P500 3 117 0,2%  Нефть 63,4 0,2%  EUR/RUB 70,7848 0,1% 
Dow 27 678 0,1%  FTSE100 7 163 0,4%  Золото 1 474 1,7%  EUR/USD 1,1105 0,0% 

Курс акций Incyte [ISIN: US45337C1027]

купить
продать

Incyte Corp. - Профиль

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.

Акционеры

Название Доля (%)
Freefloat0,99
Baker Bros. Advisors LP0,15
Baker Bros. Advisors LP0,15
The Vanguard Group, Inc.0,09
Vanguard Group, Inc. (Subfiler)0,09
Wellington Management Co. LLP0,07
Wellington Management Co. LLP0,06
Vanguard Health Care Fund0,05
T. Rowe Price Associates, Inc. (Investment Management)0,04
State Street Corp.0,04
Capital Research & Management Co. (International Investors)0,04
Capital Research & Management Co. (World Investors)0,03
BlackRock Fund Advisors0,03
BlackRock Institutional Trust Co. NA0,02
Vanguard Mid Cap Index Fund0,02

Адрес

1801 Augustine Cut-Off, 19803 Wilmington
а/я:
Телефон: 1.302.498.6700
Факс:
Вэб: http://www.incyte.com

Менеджмент

Holly Koblish
Associate Director
Phillip Liu
Associate Director-Applied Technology
Hervé Hoppenot
Chairman, President & Chief Executive Officer
Christiana Stamoulis
Chief Financial Officer & Executive Vice President
Steven H. Stein
Chief Medical Officer & Executive Vice President
Dashyant Dhanak
Chief Scientific Officer & Executive VP
Vijay Iyengar
EVP-Global Strategy & Corporate Development
Keith Mikkelson
Executive Director-Business Development
Barry P. Flannelly
Executive Vice President & General Manager
Wenqing Yao
Executive Vice President-Discovery Chemistry
Paula J. Swain
Executive Vice President-Human Resources
Lothar H. Finke
Head-Clinical Development & General Manager-Japan
Jacqualyn A. Fouse
Independent Director
Wendy L. Dixon
Independent Director
Paul Alan Brooke
Independent Director
Paul J. Clancy
Independent Director
Paul A. Friedman
Independent Director
Jean-Jacques Bienaimé
Independent Director
Julian Charles Baker
Lead Independent Director
Maria E. Pasquale
Secretary, Executive VP & General Counsel
Michael Morrissey
Senior VP & Head-Global Technical Operations
Robert Newton
Vice President-Drug Discovery Biology
Paul Trower
Vice President-Finance
Michael Charles A. Booth
Vice President-Investor Relations
Peter Langmuir
Vice President-Oncology Drug Development
Kim Solomon
Vice President-Project Management

Добавить или редактировать инструмент